HRP20120738T1 - Inhibitori kinaza akt i p70 s6 - Google Patents

Inhibitori kinaza akt i p70 s6 Download PDF

Info

Publication number
HRP20120738T1
HRP20120738T1 HRP20120738AT HRP20120738T HRP20120738T1 HR P20120738 T1 HRP20120738 T1 HR P20120738T1 HR P20120738A T HRP20120738A T HR P20120738AT HR P20120738 T HRP20120738 T HR P20120738T HR P20120738 T1 HRP20120738 T1 HR P20120738T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
attached
independently
Prior art date
Application number
HRP20120738AT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20120738T1 publication Critical patent/HRP20120738T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20120738AT 2008-11-11 2009-11-03 Inhibitori kinaza akt i p70 s6 HRP20120738T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20120738T1 true HRP20120738T1 (hr) 2012-10-31

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120738AT HRP20120738T1 (hr) 2008-11-11 2009-11-03 Inhibitori kinaza akt i p70 s6

Country Status (36)

Country Link
US (1) US8148387B2 (cg-RX-API-DMAC7.html)
EP (1) EP2358710B1 (cg-RX-API-DMAC7.html)
JP (1) JP5432275B2 (cg-RX-API-DMAC7.html)
KR (1) KR101334460B1 (cg-RX-API-DMAC7.html)
CN (1) CN102216302B (cg-RX-API-DMAC7.html)
AR (1) AR074072A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009314324B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921916A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743019C (cg-RX-API-DMAC7.html)
CO (1) CO6382114A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110240A (cg-RX-API-DMAC7.html)
CY (1) CY1113409T1 (cg-RX-API-DMAC7.html)
DK (1) DK2358710T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000129A (cg-RX-API-DMAC7.html)
EA (1) EA018947B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011048A (cg-RX-API-DMAC7.html)
ES (1) ES2391704T3 (cg-RX-API-DMAC7.html)
HN (1) HN2011001247A (cg-RX-API-DMAC7.html)
HR (1) HRP20120738T1 (cg-RX-API-DMAC7.html)
IL (1) IL211940A (cg-RX-API-DMAC7.html)
JO (1) JO2822B1 (cg-RX-API-DMAC7.html)
MA (1) MA32776B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005000A (cg-RX-API-DMAC7.html)
MY (1) MY161461A (cg-RX-API-DMAC7.html)
NZ (1) NZ592062A (cg-RX-API-DMAC7.html)
PA (1) PA8846901A1 (cg-RX-API-DMAC7.html)
PE (1) PE20110807A1 (cg-RX-API-DMAC7.html)
PL (1) PL2358710T3 (cg-RX-API-DMAC7.html)
PT (1) PT2358710E (cg-RX-API-DMAC7.html)
RS (1) RS52520B (cg-RX-API-DMAC7.html)
SI (1) SI2358710T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000207A1 (cg-RX-API-DMAC7.html)
TW (1) TWI422587B (cg-RX-API-DMAC7.html)
UA (1) UA100190C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010056563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102549B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767064C (fr) 2009-07-02 2017-11-07 Sanofi Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Akt阻害剤
WO2012136776A1 (en) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
US8927572B2 (en) * 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
HUE034979T2 (en) 2011-09-12 2018-05-02 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
EP3299362B1 (en) * 2012-11-16 2020-04-22 Merck Patent GmbH Imidazol-piperidinyl derivatives as modulators of kinase activity
ES2746756T3 (es) * 2013-03-11 2020-03-06 Merck Patent Gmbh Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa
BR112016015285A8 (pt) * 2014-02-11 2020-06-09 Merck Patent Gmbh pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
MX374576B (es) * 2016-05-20 2025-03-06 Taiho Pharmaceutical Co Ltd Derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona novedoso.
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
TW202328138A (zh) 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
JPWO2024009977A1 (cg-RX-API-DMAC7.html) * 2022-07-05 2024-01-11

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
PL2358710T3 (pl) 2012-12-31
AU2009314324A1 (en) 2010-05-20
WO2010056563A1 (en) 2010-05-20
MY161461A (en) 2017-04-14
US8148387B2 (en) 2012-04-03
TN2011000207A1 (en) 2012-12-17
EA018947B1 (ru) 2013-11-29
ZA201102549B (en) 2012-09-26
AU2009314324B2 (en) 2013-06-20
TW201022268A (en) 2010-06-16
PT2358710E (pt) 2012-10-01
ES2391704T3 (es) 2012-11-29
EP2358710A1 (en) 2011-08-24
KR101334460B1 (ko) 2013-12-02
BRPI0921916A2 (pt) 2015-12-29
RS52520B (sr) 2013-04-30
CY1113409T1 (el) 2016-06-22
HK1158203A1 (en) 2012-07-13
DOP2011000129A (es) 2016-02-29
CN102216302B (zh) 2013-08-21
IL211940A (en) 2014-01-30
AR074072A1 (es) 2010-12-22
CN102216302A (zh) 2011-10-12
CA2743019A1 (en) 2010-05-20
ECSP11011048A (es) 2011-06-30
MA32776B1 (fr) 2011-11-01
IL211940A0 (en) 2011-06-30
CA2743019C (en) 2013-08-13
JO2822B1 (en) 2014-09-15
CO6382114A2 (es) 2012-02-15
CR20110240A (es) 2011-06-09
UA100190C2 (en) 2012-11-26
JP5432275B2 (ja) 2014-03-05
EP2358710B1 (en) 2012-08-15
HN2011001247A (es) 2013-05-20
SI2358710T1 (sl) 2012-11-30
DK2358710T3 (da) 2012-09-03
PA8846901A1 (es) 2010-06-28
US20100120801A1 (en) 2010-05-13
TWI422587B (zh) 2014-01-11
NZ592062A (en) 2013-03-28
EA201170680A1 (ru) 2011-12-30
PE20110807A1 (es) 2011-10-31
MX2011005000A (es) 2011-05-25
KR20110074578A (ko) 2011-06-30
JP2012508274A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
NZ595829A (en) 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives
JP2012508274A5 (cg-RX-API-DMAC7.html)
TW200716645A (en) Macrocyclic heterocyclic aspartyl protease inhibitors
NZ602141A (en) Inhibitors of semicarabazide-sensitive amine oxidase
TW200608972A (en) Aryl-pyridine derivatives
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
NZ594597A (en) Substituted piperidines as ccr3 antagonists
NI200600262A (es) 4-fenilamino-quinazolin-6-il-amidas.
WO2008148868A8 (en) Piperidine/piperazine derivatives
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
MX2010005824A (es) Derivados de aminotiazol.
NZ603364A (en) Inhibitors of arginase and their therapeutic applications
RU2012136643A (ru) [5,6]- гетероциклическое соединение
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
JO2972B1 (en) Piperidine / piperazine derivatives
MX2018005239A (es) Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f][1,2,4]triazinona como inhibidores de fosfodiesterasa y sus usos.
TW200745032A (en) Novel heterobicyclic derivatives
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
JP2017500321A5 (cg-RX-API-DMAC7.html)